PMID- 22819619
OWN - NLM
STAT- MEDLINE
DCOM- 20130508
LR  - 20130219
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May
TI  - Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a 
      critical view.
PG  - 270-4
LID - S0305-7372(12)00143-0 [pii]
LID - 10.1016/j.ctrv.2012.06.009 [doi]
AB  - Neuroendocrine tumors (NET) are classified according to the Ki67 in 
      low-intermediate grade (Ki67<20%) and high grade (Ki67>20%). The NET of the 
      latter group are also known as neuroendocrine carcinoma (NEC), and their 
      prognosis is dismail. While in the former group biotherapy and radionuclide 
      therapy can be proposed, chemotherapy represents the only treatment usually 
      proposed for NEC. Cisplatin/etoposide combination is usually chosen based on the 
      rationale that NEC are clinically similar to small cell lung cancer. However, 
      evidence for cisplatin/etoposide in NEC is poor and controversial, and different 
      schedules and response rate have been published so far. These aspects, combined 
      with the heterogeneous characteristics of NEC, prompt us to have some doubt in 
      considering cisplatin/etoposide as the gold standard. Some evidence exists that 
      carboplatin can be used instead of cisplatin and irinotecan instead of etoposide 
      without reducing efficacy. Furthermore other drugs, as gemcitabine, oxaliplatin 
      or temozolomide can be evaluated in NEC with non-neuroendocrine component or in 
      mixed adenoneuroendocrine carcinomas. NEC are a category of NET that should be 
      deeply studied to verify if the response to cisplatin/etoposide is homogeneous 
      related to the different Ki67, different morphology and/or different primary 
      site.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Fazio, Nicola
AU  - Fazio N
AD  - Unit of Upper Gastrointestinal and Neuroendocrine Tumors, Department of Medicine, 
      European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. 
      nicola.fazio@ieo.it
FAU - Spada, Francesca
AU  - Spada F
FAU - Giovannini, Monica
AU  - Giovannini M
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120720
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Carcinoma, Neuroendocrine/*drug therapy/pathology
MH  - Gastrointestinal Neoplasms/*drug therapy/pathology
MH  - Humans
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Prognosis
EDAT- 2012/07/24 06:00
MHDA- 2013/05/09 06:00
CRDT- 2012/07/24 06:00
PHST- 2012/06/07 00:00 [received]
PHST- 2012/06/25 00:00 [accepted]
PHST- 2012/07/24 06:00 [entrez]
PHST- 2012/07/24 06:00 [pubmed]
PHST- 2013/05/09 06:00 [medline]
AID - S0305-7372(12)00143-0 [pii]
AID - 10.1016/j.ctrv.2012.06.009 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2013 May;39(3):270-4. doi: 10.1016/j.ctrv.2012.06.009. Epub 
      2012 Jul 20.